21 related articles for article (PubMed ID: 15352041)
1. Long-term serum/plasma-free culture of human cytotoxic T lymphocytes induced from peripheral blood mononuclear cells.
Liu SQ; Shiba R; Kim BS; Saijo K; Ohno T
Cancer Immunol Immunother; 1994 Nov; 39(5):279-85. PubMed ID: 7987858
[TBL] [Abstract][Full Text] [Related]
2. RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies.
McNerny DQ; Kukowska-Latallo JF; Mullen DG; Wallace JM; Desai AM; Shukla R; Huang B; Banaszak Holl MM; Baker JR
Bioconjug Chem; 2009 Oct; 20(10):1853-9. PubMed ID: 20711425
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional Glycoconjugates for Recruiting Natural Antibodies against Cancer Cells.
Liet B; Laigre E; Goyard D; Todaro B; Tiertant C; Boturyn D; Berthet N; Renaudet O
Chemistry; 2019 Dec; 25(68):15508-15515. PubMed ID: 31613028
[TBL] [Abstract][Full Text] [Related]
4. DNA-Mediated Assembly of Multispecific Antibodies for T Cell Engaging and Tumor Killing.
Pan L; Cao C; Run C; Zhou L; Chou JJ
Adv Sci (Weinh); 2020 Jan; 7(2):1900973. PubMed ID: 31993277
[TBL] [Abstract][Full Text] [Related]
5. Integrin targeted delivery of chemotherapeutics.
Chen K; Chen X
Theranostics; 2011 Feb; 1():189-200. PubMed ID: 21547159
[TBL] [Abstract][Full Text] [Related]
6. Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu-7 antigen.
Phillips JH; Lanier LL
J Immunol; 1986 Mar; 136(5):1579-85. PubMed ID: 2419407
[TBL] [Abstract][Full Text] [Related]
7. CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro.
Molema G; Tervaert JW; Kroesen BJ; Helfrich W; Meijer DK; de Leij LF
Br J Cancer; 2000 Jan; 82(2):472-9. PubMed ID: 10646907
[TBL] [Abstract][Full Text] [Related]
8. [Anti-tumor effect of cytotoxic T lymphocytes induced by soluble antigen of ovarian carcinoma and anti-CD3 monoclonal antibody on ovarian carcinoma].
Zhang Q; Wan Y; Zhai H
Zhonghua Fu Chan Ke Za Zhi; 1998 Jun; 33(6):355-7. PubMed ID: 10806675
[TBL] [Abstract][Full Text] [Related]
9. Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study.
Schraa AJ; Kok RJ; Moorlag HE; Bos EJ; Proost JH; Meijer DK; de Leij LF; Molema G
Int J Cancer; 2002 Dec; 102(5):469-75. PubMed ID: 12432548
[TBL] [Abstract][Full Text] [Related]
10. Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics.
Kok RJ; Schraa AJ; Bos EJ; Moorlag HE; Asgeirsdóttir SA; Everts M; Meijer DK; Molema G
Bioconjug Chem; 2002; 13(1):128-35. PubMed ID: 11792188
[TBL] [Abstract][Full Text] [Related]
11. RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward alphavbeta3-expressing endothelial cells.
Schraa AJ; Kok RJ; Botter SM; Withoff S; Meijer DK; de Leij LF; Molema G
Int J Cancer; 2004 Nov; 112(2):279-85. PubMed ID: 15352041
[TBL] [Abstract][Full Text] [Related]
12. Targeted cellular immunotherapy with bifunctional antibodies.
Nelson H
Cancer Cells; 1991 May; 3(5):163-72. PubMed ID: 1832553
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
